7 results

  • amzeeq

    (Minocycline)
    Journey Medical Corporation
    AMZEEQ is indicated for the topical treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients aged 9 and older. It is not intended for treating infections and should be used to prevent drug-resistant bacteria development.

  • emrosi

    (Minocycline Hydrochloride Extended-Release)
    Journey Medical Corporation
    EMROSI is indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. It is not evaluated for infection treatment or prevention and should be used as indicated to avoid drug-resistant bacteria.

  • exelderm

    (Sulconazole Nitrate)
    Journey Medical Corporation
    EXELDERM (sulconazole nitrate, USP) CREAM, 1.0% is indicated for treating tinea pedis (athlete's foot), tinea cruris, tinea corporis, and tinea versicolor, caused by specific fungi including Trichophyton rubrum and Microsporum canis, among others. Efficacy for some organisms was studied in limited cases.

  • qbrexza

    (glycopyrronium)
    Journey Medical Corporation
    Qbrexza is indicated for the topical treatment of primary axillary hyperhidrosis in adults and pediatric patients aged 9 years and older.

  • targadox

    (doxycycline hyclate)
    Journey Medical Corporation
    TARGADOX® (doxycycline) is indicated for treating infections caused by susceptible bacteria, including certain rickettsial diseases, respiratory infections, and Chlamydia infections. It is also used for prophylaxis against malaria in short-term travelers. The drug should be used to prevent antibiotic resistance.

  • ximino

    (minocycline hydrochloride)
    Journey Medical Corporation
    Ximino is indicated for treating inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 12 and older. Its use should be limited to avoid drug-resistant bacteria, and it has not been shown effective for non-inflammatory lesions or for infections. Safety beyond 12 weeks is not established.

  • zilxi

    (Minocycline)
    Journey Medical Corporation
    ZILXI is indicated for treating inflammatory lesions of rosacea in adults. It has not been evaluated for infection treatment and should be used as directed to prevent drug-resistant bacteria and maintain the effectiveness of other antibacterial drugs.